{"id":456310,"date":"2021-03-11T16:08:13","date_gmt":"2021-03-11T21:08:13","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=456310"},"modified":"2021-03-11T16:08:13","modified_gmt":"2021-03-11T21:08:13","slug":"dr-neil-hattangadi-joins-intersect-ents-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/","title":{"rendered":"Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors"},"content":{"rendered":"

<\/p>\n

Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors<\/b><\/p>\n

MENLO PARK, Calif.–(BUSINESS WIRE<\/a>)–
\nIntersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (\u201cENT\u201d) medical technology leader dedicated to transforming patient care, today announced Neil Hattangadi, M.D., M.Sc. joined the Intersect ENT Board of Directors. Dr. Hattangadi will serve as a member of the Nominating and Corporate Governance Committee of the Board.\n<\/p>\n

\n\u201cWe are thrilled to have Neil join the Intersect ENT Board. He brings a wealth of experience in building successful companies as well as highly relevant ENT expertise,\u201d said Thomas A. West, President and Chief Executive Officer of Intersect ENT. \u201cNeil is a clinician, innovator and business leader with an exceptional track record. His experience and inquisitive and collaborative demeanor make him an excellent fit for our Board.\u201d\n<\/p>\n

\n\u201cI\u2019m excited to have the opportunity to contribute to Intersect ENT,\u201d said Dr. Hattangadi. \u201cI look forward to helping make localized drug delivery with the PROPEL and SINUVA implants the standard of care in rhinosinusitis while also helping the management team expand Intersect ENT\u2019s product and technology portfolio across the continuum of ENT care.\u201d\n<\/p>\n

\nDr. Hattangadi is Co-Founder and Chief Executive Officer of Cortica Inc., a high-growth technology-enabled autism service provider. Previously, he served as President and Chief Operating Officer of ENT start-up Spirox Inc. where he launched the Latera implant for Nasal Airway Obstruction. Spirox was sold to Entellus Medical, another ENT company. Earlier in his career Dr. Hattangadi ran the global Peripheral Vascular business at Royal Phillips and Volcano Corporation. Dr. Hattangadi currently serves as a Board member of the venous stent company Vesper Medical. Dr. Hattangadi received a B.S.E. from Duke University, M.Sc. as a Rhodes Scholar from Oxford University and M.D. from Harvard Medical School.\n<\/p>\n

About Intersect ENT<\/b><\/p>\n

\nIntersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company\u2019s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company\u2019s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company’s PROPEL\u00ae and SINUVA\u00ae sinus implants and extend its geographic reach.\n<\/p>\n

\nFor additional information on the Company or the products including risks and benefits please visit www.IntersectENT.com<\/a><\/span>. For more information about PROPEL\u00ae (mometasone furoate) sinus implants and SINUVA\u00ae (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com<\/a><\/span> and www.SINUVA.com<\/a><\/span>.\n<\/p>\n

\nIntersect ENT\u00ae, PROPEL\u00ae and SINUVA\u00ae, are registered trademarks of Intersect ENT, Inc.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThe forward-looking statements in this press release are based on Intersect ENT\u2019s current expectations and inherently involve significant risks and uncertainties. These statements and risks include: the duration and severity of the COVID-19 pandemic is unknown and could continue, and be more severe, than Intersect ENT currently expects; the unknown state of the U.S. economy following the pandemic; the level of demand for Intersect ENT\u2019s products as the pandemic subsides; the ability of Intersect ENT to effectively and efficiently resume full commercial and manufacturing operations; the time it will take for the economy to recover from the pandemic; and the sufficiency of capital to run the Company through 2022. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, and others which are described in the Company\u2019s latest Form 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (www.sec.gov<\/a>). Intersect ENT does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210311005277\/en\/<\/a><\/span><\/p>\n

IR Contact:
\n<\/b>
Randy Meier, 650-641-2105
\n
Executive Vice-President & CFO
\n
ir@intersectENT.com
\n<\/a><\/p>\n

Media Contact:
\n<\/b>
Erich Sandoval, 917-497-2867
\n
Finn Partners for Intersect ENT
\n
IntersectENT@finnpartners.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> General Health Health Surgery Medical Devices<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors MENLO PARK, Calif.–(BUSINESS WIRE)– Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (\u201cENT\u201d) medical technology leader dedicated to transforming patient care, today announced Neil Hattangadi, M.D., M.Sc. joined the Intersect ENT Board of Directors. Dr. Hattangadi will serve as a member of the Nominating and Corporate Governance Committee of the Board. \u201cWe are thrilled to have Neil join the Intersect ENT Board. He brings a wealth of experience in building successful companies as well as highly relevant ENT expertise,\u201d said Thomas A. West, President and Chief Executive Officer of Intersect ENT. \u201cNeil is a clinician, innovator and business leader with an exceptional track record. His experience and inquisitive … <\/p>\n

Continue reading “Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-456310","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nDr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors MENLO PARK, Calif.–(BUSINESS WIRE)– Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (\u201cENT\u201d) medical technology leader dedicated to transforming patient care, today announced Neil Hattangadi, M.D., M.Sc. joined the Intersect ENT Board of Directors. Dr. Hattangadi will serve as a member of the Nominating and Corporate Governance Committee of the Board. \u201cWe are thrilled to have Neil join the Intersect ENT Board. He brings a wealth of experience in building successful companies as well as highly relevant ENT expertise,\u201d said Thomas A. West, President and Chief Executive Officer of Intersect ENT. \u201cNeil is a clinician, innovator and business leader with an exceptional track record. His experience and inquisitive … Continue reading "Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-11T21:08:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210311005277r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors\",\"datePublished\":\"2021-03-11T21:08:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\\\/\"},\"wordCount\":749,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210311005277r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\\\/\",\"name\":\"Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210311005277r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-03-11T21:08:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210311005277r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210311005277r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors - Market Newsdesk","og_description":"Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors MENLO PARK, Calif.–(BUSINESS WIRE)– Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (\u201cENT\u201d) medical technology leader dedicated to transforming patient care, today announced Neil Hattangadi, M.D., M.Sc. joined the Intersect ENT Board of Directors. Dr. Hattangadi will serve as a member of the Nominating and Corporate Governance Committee of the Board. \u201cWe are thrilled to have Neil join the Intersect ENT Board. He brings a wealth of experience in building successful companies as well as highly relevant ENT expertise,\u201d said Thomas A. West, President and Chief Executive Officer of Intersect ENT. \u201cNeil is a clinician, innovator and business leader with an exceptional track record. His experience and inquisitive … Continue reading \"Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-11T21:08:13+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210311005277r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors","datePublished":"2021-03-11T21:08:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/"},"wordCount":749,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210311005277r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/","name":"Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210311005277r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-03-11T21:08:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210311005277r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210311005277r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-neil-hattangadi-joins-intersect-ents-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dr. Neil Hattangadi Joins Intersect ENT\u2019s Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=456310"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456310\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=456310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=456310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=456310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}